570 South Preston Street
Louisville, KY 40202
United States
502-398-9250
https://talaristx.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 112
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Scott Requadt J.D., L.L.B., M.B.A., MBA | Pres, CEO, Sec. & Director | 544.76k | N/A | 1968 |
Dr. Suzanne T. Ildstad M.D. | Founder, Chief Scientific Officer & Director | 486.07k | N/A | 1953 |
Ms. Nancy Krieger M.D. | Chief Medical Officer | 482.76k | N/A | 1967 |
Ms. Mary Kay Fenton | Chief Financial Officer | N/A | N/A | 1964 |
Mr. Michael Zdanowski | Chief Technology Officer | N/A | N/A | 1967 |
Ms. Suzanne Tollerud | VP of Corp. Devel. & Treasurer | N/A | N/A | N/A |
Mr. Roderick D. Purdy | VP of HR | N/A | N/A | 1957 |
Mr. Eric Gornstein | Head of New Product Planning | N/A | N/A | N/A |
Ms. Farah Natoli | Head of Portfolio & Program Management | N/A | N/A | N/A |
Mr. Colby Suire Ph.D. | Head of R&D | N/A | N/A | N/A |
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
Talaris Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.